Home / About Us / Social Conscience
BioPharm is a conscious corporation. We believe that game changing technologies like ours should be leveraged to serve the community. Here is how we do that.
Today more than ever, sustainability and ethical deployment of resources are key factors for investors. Our purpose in developing health technologies is to see those technologies used in rebuilding our communities, by supplementing state health infrastructure.
As a developer of technologies for the management and treatment of trauma related illnesses (including alcoholism, addiction, anxiety and PTSD) at a time where state health services are under resourced, and over burdened, BioPharm’s vision is to not only develop treatments and wellness enhancing technologies, but to also establish self funding community projects to enable members of low income demographics to access privately subsidised products and services to support their return to stable mental health.
The COVID pandemic followed by economic recession against a backdrop of eroded trust in government and state health services has set conditions for a global wave of mental health and trauma related conditions such as depression, anxiety, PTSD, alcoholism and other addictions. Public concern at novel pharmaceutical interventions employed has led a swing back to targeted natural health solutions.
BioPharm’s partnership with Everlasting Foundation, is committed to researching the most effective natural and nature inspired harm reduction technologies for trauma recovery, addiction interruption, cognitive restoration and all forms of drug detoxification. The partnership is committed to developing consumer level products targeted at those with disposable income, and subsidised or free on demand products for those of limited means.
Inspired by the hybrid limited partnership model of world leading software developer OpenAI, (developers of ChatGPT) BioPharm and Everlasting Foundation’s capped return offer aims to attract conscious investors with the oportunity to invest in a community asset, receive generous returns, with knowledge that in the long run you are establishing a self funded independant natural health provider.
To date formulations have been developed for alcohol cessation support, methamphetamine addiction recovery, opiate, cannabis and benzodiazepine drug withdrawal. The foundation intends to establish community centres to bring them to target audience, funded by ongoing operations.
Psilocybin mushrooms have been used by indigenous cultures for millennia for their therapeutic and mystical benefits. Western cultures have been denied this natural gift due to fear and taboo. Now, science has rediscovered its potential, and modern man is gaining access to this ancient tool.
Research is showing microdosing LSD (taking tiny amounts) to have powerful benefits, but the potential for overdose makes it unlikely to be allowed for public use. BioPharm have developed similar products with a ceiling level of effect to prevent overdose.
Ketamine is a popular surgical anaesthetic found to have mental health benefits, such as relief of treatment resistant depression, but is toxic to bladder. BioPharm team have worked on a number of improvements to this molecule.
MDMA is fast becoming a popular medicine for a variety of symptoms, but is toxic to heart and brain. BioPharm's EASE project has safer alternatives under development.
Stimulants such as cocaine and methamphetamine are widely used in the community but can have devastating consequences. Developing substitution drugs with less risk is becoming an attractive policy solution and we are working on the technology to get there.
Powered by WhatsApp Chat
